Literature DB >> 3264006

Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.

M H De Baets1, J Verschuuren, M R Daha, P J van Breda Vriesman.   

Abstract

The effect of target organ manipulation by means of denervation and treatment with anabolic steroids on the severity of disease in EAMG was assessed in inbred rats. Unilateral limb denervation, a procedure known to increase the AChR content of muscle, 'protected' the denervated leg against antibody-mediated AChr loss in acute EAMG induced by passive transfer of mAb 35 directed against the main immunogenic region. Also in chronic EAMG, brought about by immunizing rats with AChR in complete Freund's adjuvant, the AChR loss of the denervated leg was about one fourth (13.5 vs. 53%) of the control leg. In both acute and chronic EAMG the amount of AChR complexed with antibody was lower in the denervated leg. This lower AChR occupancy with antibody in the denervated leg occurred also in conditions of marked antibody excess and was therefore due to enhanced AChR synthesis. Next the effect of treatment with a weakly virilizing anabolic steroid nandrolone in chronic and acute EAMG was examined in order to examine whether a hypothesized enhanced synthesis of AChR would protect animals from disease. In the absence of an immunosuppressive effect, in terms of concentration of antibodies to AChR, nandrolone treatment protected the rats from severe disease in the chronic EAMG model as shown by the fact that of the 9 rats 6 showed mild (1+) disease and 3 no disease at all; conversely 6 out of 9 control rats showed severe (3+) disease. Rats treated with nandrolone showed a 48 +/- 1.7% loss of AChR compared to a loss of 58 +/- 3.6% in the control rats, suggesting enhanced AChR synthesis. When nandrolone-pretreated rats were given acute EAMG by passive transfer of mAb 35 a paradoxical effect was seen. In contrast to the controls all of the rats pretreated with nandrolone showed severe signs of EAMG; this was associated with a higher loss of AChR and increased consumption of complement C4 as suggested by decreased concentrations of C4 in the serum. Results show increased AChR synthesis to protect against chronic EAMG both in terms of clinical disease (nandrolone) as well as AChR loss (nandrolone, denervation). In addition it was shown that nandrolone increases serum C4 consumption which in the complement-dependent acute EAMG model causes enhancement of the severity of clinical disease and increased AChR loss.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264006     DOI: 10.1007/bf02918135

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  40 in total

Review 1.  Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome.

Authors:  J Lindstrom
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

2.  Isolation of the fourth component (C4) of rat complement.

Authors:  M R Daha; L A van ES
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

3.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities.

Authors:  J A Gelfand; R J Sherins; D W Alling; M M Frank
Journal:  N Engl J Med       Date:  1976-12-23       Impact factor: 91.245

4.  Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.

Authors:  A Bionda; M H De Baets; S J Tzartos; J M Lindstrom; W O Weigle; A N Theophilopoulos
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

5.  Mapping of surface structures of electrophorus acetylcholine receptor using monoclonal antibodies.

Authors:  S J Tzartos; D E Rand; B L Einarson; J M Lindstrom
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

6.  Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients.

Authors:  H J Oosterhuis; P C Limburg; E Hummel-Tappel; T H The
Journal:  J Neurol Sci       Date:  1983-03       Impact factor: 3.181

7.  Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects.

Authors:  J M Lindstrom; V A Lennon; M E Seybold; S Whittingham
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

8.  Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.

Authors:  S J Tzartos; M E Seybold; J M Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

9.  Monoclonal antibodies to human thyroglobulin as probes for thyroglobulin structure.

Authors:  M H De Baets; R Theunissen; K Kok; J J de Vijlder; P J van Breda Vriesman
Journal:  Endocrinology       Date:  1987-03       Impact factor: 4.736

10.  Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs.

Authors:  V A Lennon; J M Lindstrom; M E Seybold
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

2.  Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.

Authors:  Mario Losen; Pilar Martinez-Martinez; Peter C Molenaar; Konstantinos Lazaridis; Socrates Tzartos; Talma Brenner; Rui-Sheng Duan; Jie Luo; Jon Lindstrom; Linda Kusner
Journal:  Exp Neurol       Date:  2015-03-18       Impact factor: 5.330

Review 3.  Autoimmune synaptopathies.

Authors:  Sarah J Crisp; Dimitri M Kullmann; Angela Vincent
Journal:  Nat Rev Neurosci       Date:  2016-02       Impact factor: 34.870

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.